JPMorgan Chase & Co. Has $4.86 Million Holdings in Establishment Labs Holdings Inc. $ESTA

JPMorgan Chase & Co. cut its holdings in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 68.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 118,584 shares of the company’s stock after selling 254,528 shares during the quarter. JPMorgan Chase & Co.’s holdings in Establishment Labs were worth $4,861,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in ESTA. Quarry LP bought a new stake in shares of Establishment Labs in the third quarter valued at approximately $34,000. State of Wyoming bought a new position in Establishment Labs during the 3rd quarter worth $71,000. Osaic Holdings Inc. raised its holdings in Establishment Labs by 900.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after acquiring an additional 1,800 shares in the last quarter. PharVision Advisers LLC acquired a new position in Establishment Labs in the 3rd quarter valued at $203,000. Finally, Brian Low Financial Group LLC bought a new stake in shares of Establishment Labs during the 3rd quarter valued at $223,000. 72.91% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ESTA has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research report on Friday, March 27th. JPMorgan Chase & Co. upped their price objective on shares of Establishment Labs from $71.00 to $80.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. BTIG Research increased their price objective on shares of Establishment Labs from $86.00 to $88.00 and gave the stock a “buy” rating in a research note on Tuesday, February 24th. Wall Street Zen lowered shares of Establishment Labs from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Finally, Citigroup dropped their target price on shares of Establishment Labs from $81.00 to $74.00 and set a “neutral” rating for the company in a research report on Wednesday, March 11th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $86.86.

Establishment Labs Trading Down 0.7%

Shares of ESTA opened at $58.31 on Friday. Establishment Labs Holdings Inc. has a 52-week low of $26.56 and a 52-week high of $83.31. The business’s fifty day moving average is $68.20 and its 200-day moving average is $62.41. The company has a debt-to-equity ratio of 10.51, a quick ratio of 2.00 and a current ratio of 3.04. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of -33.51 and a beta of 1.08.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.13. The business had revenue of $64.62 million during the quarter, compared to the consensus estimate of $63.80 million. Establishment Labs had a negative return on equity of 201.79% and a negative net margin of 24.19%.Establishment Labs’s revenue for the quarter was up 45.2% on a year-over-year basis. During the same period in the prior year, the company earned ($1.19) EPS. Equities analysts anticipate that Establishment Labs Holdings Inc. will post -2.41 EPS for the current fiscal year.

Insider Activity at Establishment Labs

In other news, Director Quiros Juan Jose Chacon sold 33,925 shares of the stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $60.39, for a total value of $2,048,730.75. Following the completion of the transaction, the director owned 1,223,579 shares of the company’s stock, valued at approximately $73,891,935.81. This represents a 2.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 11.09% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.